Accelerating and simplifying the development and manufacturing process of cell and gene therapies.
Apparatus
-
-
Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
-
In a rural area of Britain, a team of 100 scientists and engineers first used low-cost technologies to develop mobile phones and the aviation industry. Later, these technologies were used to research robot arms, which can be specially used for minimally invasive surgery.
-
Apparatus
New CAR-T Therapy CB-010, Granted Two FDA Designations And Three Patients Are Cancer-Free For Six Months!
According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
Apparatus
Cancer Vaccine Shows Its Power! Survival Of Patients With Advanced Colorectal Cancer Extended By More Than 3 Times!
Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.
-
Apparatus
Hutchison Pharmaceuticals Announces Approval Of Cd73 Monoclonal Antibody Mupadolimab In Phase I/Ib Clinical Trial In China
The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.
-
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
-
HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.
-
Apparatus
Major Breakthrough In 27 Years! This Cancer Vaccine Has Kept Deadly Brain Cancer Patients Alive For Over 8 Years!
A dendritic cell vaccine has shown excellent results in the treatment of glioblastoma, significantly extending the survival of patients with a good safety profile, according to new data from a global clinical trial. To date, patients who have benefited for the longest time have survived for more than eight years.
-
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.